Doximity (NYSE:DOCS) Earns Hold Rating from Truist Financial

Doximity (NYSE:DOCS)‘s stock had its “hold” rating reaffirmed by investment analysts at Truist Financial in a research report issued on Thursday, Marketbeat reports. They presently have a $19.00 target price on the stock, down from their prior target price of $29.00. Truist Financial’s price objective points to a potential upside of 0.40% from the company’s previous close.

DOCS has been the topic of several other reports. KeyCorp lowered shares of Doximity from an “overweight” rating to a “sector weight” rating in a research note on Thursday. Bank of America dropped their price objective on shares of Doximity from $56.00 to $47.00 and set a “buy” rating on the stock in a research note on Thursday, April 16th. Mizuho dropped their price objective on shares of Doximity from $34.00 to $26.00 and set a “neutral” rating on the stock in a research note on Thursday. Needham & Company LLC dropped their price objective on shares of Doximity from $55.00 to $27.00 and set a “buy” rating on the stock in a research note on Thursday. Finally, Robert W. Baird restated a “neutral” rating and issued a $18.00 price objective (down from $40.00) on shares of Doximity in a research note on Thursday. Two equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and fourteen have given a Hold rating to the company’s stock. According to data from MarketBeat, Doximity has a consensus rating of “Hold” and an average target price of $30.62.

Doximity Price Performance

Shares of NYSE:DOCS opened at $18.93 on Thursday. The stock’s fifty day moving average is $23.94. Doximity has a 12 month low of $17.15 and a 12 month high of $76.51. The firm has a market cap of $3.50 billion, a price-to-earnings ratio of 19.12, a P/E/G ratio of 1.28 and a beta of 1.36.

Doximity declared that its board has approved a share repurchase plan on Thursday, February 5th that allows the company to repurchase $500.00 million in outstanding shares. This repurchase authorization allows the company to repurchase up to 8% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s board believes its stock is undervalued.

Insiders Place Their Bets

In other Doximity news, insider Siddharth Sitaram sold 2,427 shares of Doximity stock in a transaction on Friday, April 10th. The shares were sold at an average price of $21.09, for a total value of $51,185.43. Following the transaction, the insider directly owned 86,705 shares in the company, valued at approximately $1,828,608.45. The trade was a 2.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Kira Scherer Wampler sold 9,000 shares of Doximity stock in a transaction on Thursday, May 7th. The shares were sold at an average price of $26.06, for a total transaction of $234,540.00. Following the completion of the transaction, the director owned 19,839 shares in the company, valued at approximately $517,004.34. This represents a 31.21% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 18,055 shares of company stock worth $456,061. 31.30% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in DOCS. Carmignac Gestion increased its stake in shares of Doximity by 355.9% during the fourth quarter. Carmignac Gestion now owns 1,893,026 shares of the company’s stock worth $83,831,000 after acquiring an additional 1,477,798 shares during the period. SG Americas Securities LLC increased its stake in shares of Doximity by 3,403.2% during the first quarter. SG Americas Securities LLC now owns 1,408,597 shares of the company’s stock worth $32,820,000 after acquiring an additional 1,368,388 shares during the period. Northwestern Mutual Wealth Management Co. increased its stake in shares of Doximity by 325,436.6% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 1,298,891 shares of the company’s stock worth $57,515,000 after acquiring an additional 1,298,492 shares during the period. Federated Hermes Inc. increased its stake in shares of Doximity by 3,422.7% during the fourth quarter. Federated Hermes Inc. now owns 1,249,085 shares of the company’s stock worth $55,309,000 after acquiring an additional 1,213,627 shares during the period. Finally, Capital World Investors increased its stake in shares of Doximity by 25.7% during the third quarter. Capital World Investors now owns 5,381,431 shares of the company’s stock worth $393,652,000 after acquiring an additional 1,101,848 shares during the period. 87.19% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Doximity

Here are the key news stories impacting Doximity this week:

• Positive Sentiment: Doximity said revenue still grew year over year, and its earnings call highlighted strong engagement from AI tool adoption, suggesting the platform is gaining traction with physicians. Doximity Stock Falls on Q4 Earnings Miss, Revenues Beat, Margins Down
• Positive Sentiment: Doximity announced a partnership with Aledade to bring clinical AI tools into value-based care workflows, which could support longer-term adoption and monetization. DOCS Teams Up With Aledade to Bring Clinical AI to Value-Based Care
• Neutral Sentiment: Several articles noted the stock has become technically oversold after a sharp selloff, which could set up a bounce if sentiment improves. Down 25.7% in 4 Weeks, Here’s Why Doximity (DOCS) Looks Ripe for a Turnaround
• Negative Sentiment: Doximity missed quarterly earnings estimates and issued fiscal 2027 revenue guidance below Wall Street expectations, raising concerns that growth is slowing. Doximity, Inc. (DOCS) Q4 2026 Earnings Call Transcript
• Negative Sentiment: Analysts turned more cautious, with multiple firms cutting price targets or downgrading the stock, including Baird, Wells Fargo, BTIG, JPMorgan, Mizuho, BMO, Needham and Truist. DOCS vs. HIMS: Which Stock Is the Better Value Option?
• Negative Sentiment: Investor caution also increased after insider selling was disclosed, even though it was tied to a pre-arranged 10b5-1 plan and tax withholding. Doximity (NYSE:DOCS) Insider Siddharth Sitaram Sells 2,309 Shares

About Doximity

Doximity, trading as DOCS, operates a digital professional network and communications platform designed primarily for clinicians. Headquartered in San Francisco, the company connects physicians, nurse practitioners, physician assistants and other healthcare professionals, providing tools that streamline clinical communication, telehealth delivery and access to specialty-specific medical information. Its platform is positioned as a professional hub where clinicians manage their workflows, stay current with medical news and collaborate securely with peers.

The company’s offerings include secure messaging and video telehealth capabilities that enable clinicians to consult with patients and colleagues while protecting patient information.